Revenue Plunges 76% as Quantum Cyber Pivots to Cybersecurity & Pancreatic Cancer
QUCY has more than doubled off its 52-week low of $0.3 on elevated volume (5.4× avg).
Summary
Quantum Cyber N.V. reported Q1 2026 revenue of $281.9K, marking a substantial 75.7% year-over-year decline, alongside an EPS loss of ($0.43). The company announced a significant strategic pivot, exiting its colorectal cancer screening business and selling related intellectual property. Its new focus areas are a blood-based pancreatic cancer program and post-quantum cybersecurity efforts. This follows the company's recent expansion of its At-The-Market (ATM) equity program to $100 million and a prior 10-K filing that raised substantial doubt about its ability to continue as a going concern. The drastic revenue decline and complete overhaul of the business model introduce significant uncertainty and risk for this micro-cap company, despite the potential long-term benefits of the new strategic direction. Investors will closely monitor the execution of the new strategy, progress in both the pancreatic cancer program and cybersecurity initiatives, and the company's ability to secure further financing.
At the time of this announcement, QUCY was trading at $3.36 on NASDAQ in the Technology sector, with a market capitalization of approximately $43.3M. The 52-week trading range was $0.30 to $4.93. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.